Notice of Preliminary Results

RNS Number : 5836O

Faron Pharmaceuticals Oy

10 February 2016

 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Notice of Preliminary Results

TURKU - FINLAND, 10 February 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, will announce its Preliminary Results for the year ended 31^st December, 2015 on Thursday 10^th March, 2016.

Dr Markku Jalkanen, Chief Executive Officer, will host a presentation for analysts at 9am GMT on the day at Hume Brophy offices, 55 King William Street, London EC4R 9AD.

For more information contact:

Faron Pharmaceuticals Ltd

Katja Wallenlind

Phone [phone]
E-mail: [e-mail]

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: [phone]

Whitman Howard Limited, Nominated Broker

Niall Devins, Francis North

Phone: [phone]

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: [phone]

E-mail: [e-mail]

About Faron Pharmaceuticals Oy

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition for which there is currently no approved pharmaceutical treatment. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating.

Further information is available at www.faronpharmaceuticals.com.

 

END

 

 

NORVKLFBQLFEBBF